Humans Laser Coagulation Laser Therapy Lasers Solid-State Male Non-Randomized Controlled Trials as Topic/statistics & numerical data Prostatic Hyperplasia/complications Quality of Life Randomized Controlled Trials as Topic/statistics & numerical data *Thulium Transurethral Resection of Prostate Treatment Outcome Ureteral Obstruction/etiology 2-micron Benign prostatic obstruction Plasmakinetic resection of prostate Safety and efficacy Thulium laser VapoResection of the prostate Thulium laser Transurethral resection of the prostate

5-alpha Reductase Inhibitors/pharmacology Blood Loss Surgical/*prevention & control Blood Transfusion Dutasteride/*pharmacology Hemoglobins/analysis Humans Male Microcirculation Prospective Studies Prostate Prostatic Hyperplasia Randomized Controlled Trials as Topic Retrospective Studies *Transurethral Resection of Prostate Treatment Outcome Vascular Endothelial Growth Factor A/metabolism Benign prostatic hyperplasia Dutasteride Intraoperative blood loss Meta-analysis Transurethral resection of the prostate

B-TURP HoLEP benign prostatic hyperplasia Meta-analysis

Benign prostatic hyperplasia Lower urinary tract symptoms systematic review

Surgical Treatments Benign Prostatic Hyperplasia Male Erectile Function Meta-Analysis

Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Meta-analysis

Transurethral enucleation of the prostate transvesical open prostatectomy benign prostatic hyperplasia meta-analysis

Benign prostatic hyperplasia surgical treatments meta-analysis

Greenlight high-performance system 120-W laser vaporization transurethral resection of the prostate benign prostatic hyperplasia meta-analysis

Thulium Laser Resection Plasmakinetic Resection of Prostates Benign Prostate Hyperplasia Meta-Analysis

Lasers benign prostatic hyperplasia meta-analysis

Smoking habits benign prostatic hyperplasia systematic review meta-analysis

Humans Immune Checkpoint Inhibitors/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/drug therapy Proportional Hazards Models Eastern Cooperative Oncology Group Immune checkpoint inhibitor Performance status Urothelial carcinoma

Bladder-sparing strategy Clinical complete response Localized muscle-invasive bladder cancer Neoadjuvant Systemic treatment

Male Humans *Stomach Neoplasms/genetics *Urinary Bladder Neoplasms/genetics Urinary Bladder Membrane Proteins RNA Messenger Antigens Neoplasm/genetics Neoplasm Proteins GPI-Linked Proteins/genetics Psca cancer risk polymorphism rs2294008 (C/T)

Humans *Transurethral Resection of Bladder Neoplasm Recurrence Local/pathology *Urinary Bladder Neoplasms/diagnosis/surgery/pathology Prognosis Urologic Surgical Procedures Cystectomy Bladder cancer Css Os Pfs Rfs Transurethral resection of bladder tumors financial ties to disclose.

Bcg Instillation Intravesical Low dose Non–muscle-invasive bladder cancer

膀胱癌 吉西他滨 表柔比星 膀胱灌注 系统评价

Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

膀胱癌 MALAT1 Meta分析